HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Infective endocarditis due to high level aminoglycoside resistant Enterococcus faecalis and methicillin resistant coagulase-negative staphylococci presenting with rheumatic manifestations].

Abstract
Infective endocarditis has variable clinical presentations and may present with rheumatologic manifestations. Infective endocarditis due to high level aminoglycoside resistant enterococci represents a severe therapeutic challenge as none of the currently recommended treatment regimens are bactericidal against these isolates. In this report, a case of infective endocarditis with double aetiology, high level aminoglycoside resistant Enterococcus faecalis together with methicillin-resistant coagulase-negative staphylococci (MR-CNS), presenting with leukocytoclastic vasculitis and rapidly progressive glomerulonephritis, has been presented. A 48-years-old woman was admitted to our hospital with malaise and non-pruritic purpural rush on her lower extremities. On admission she had no fever or leukocytosis. Skin biopsy showed leukocytoclastic vasculitis and steroid therapy was started. On 12th day of admission rapidly progressive glomerulonephritis was diagnosed and she received plasmapheresis and haemodialysis support. Transthoracic echocardiography (TTE) demonstrated 1 x 1.5 cm vegetation on the mitral valve. An initial diagnosis of infective endocarditis was made and empirical treatment with vancomycin and gentamicin was started. All blood cultures yielded high level aminoglycoside resistant E. faecalis and additionally two of them yielded MR-CNS. Vancomycin was administered in combination with high dose ampicillin and repeated blood cultures taken after administration of ampicillin, revealed no growth. The patient remained afebrile, renal functions improved and a repeat TTE done on 20th day of ampicillin therapy showed waning of the vegetation. On 42nd day of treatment repeat TTE showed new vegetation on the mitral valve and severe valve insufficiency, so the patient was scheduled for mitral valve replacement. She was treated for 12 weeks with vancomycin and ampicillin and recovered successfully. In conclusion; infective endocarditis should be considered in the differential diagnosis of leukocytoclastic vasculitis and rapidly progressive glomerulonephritis. Physicians should document their treatment outcomes and experience with high level aminoglycoside resistant enterococcal infective endocarditis, which is a therapeutic challenge, so that the best therapeutic options can be identified.
AuthorsNihal Pişkin, Deniz Akduman, Hande Aydemir, Güven Celebi, Nefise Oztoprak, Elif Aktaş
JournalMikrobiyoloji bulteni (Mikrobiyol Bul) Vol. 42 Issue 3 Pg. 509-14 (Jul 2008) ISSN: 0374-9096 [Print] Turkey
Vernacular TitleRomatolojik bulgularla seyreden, yüksek düzey aminoglikozid direnci gösteren Enterococcus faecalis ve metisiline dirençli koagülaz-negatif stafilokokun etken olduğu enfektif endokardit olgusu.
PMID18822897 (Publication Type: Case Reports, English Abstract, Journal Article)
Chemical References
  • Aminoglycosides
  • Anti-Bacterial Agents
  • Gentamicins
  • Vancomycin
  • Ampicillin
Topics
  • Aminoglycosides (pharmacology, therapeutic use)
  • Ampicillin (therapeutic use)
  • Anti-Bacterial Agents (pharmacology, therapeutic use)
  • Drug Resistance, Multiple, Bacterial
  • Drug Therapy, Combination
  • Endocarditis, Bacterial (complications, drug therapy, microbiology)
  • Enterococcus faecalis (drug effects)
  • Female
  • Gentamicins (therapeutic use)
  • Glomerulonephritis (etiology)
  • Gram-Positive Bacterial Infections (complications, drug therapy, microbiology)
  • Humans
  • Methicillin-Resistant Staphylococcus aureus
  • Middle Aged
  • Staphylococcal Infections (complications, drug therapy, microbiology)
  • Vancomycin (therapeutic use)
  • Vasculitis, Leukocytoclastic, Cutaneous (etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: